Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirati Therapeutics
(NQ:
MRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirati Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 07, 2022
Via
Benzinga
Mid-Day Market Update: Nasdaq Turns Higher; REV Group Shares Plunge
June 07, 2022
U.S. stocks pared losses, with the Nasdaq Composite turning higher midway through trading on Tuesday.
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
June 07, 2022
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) gained 70% to $0.4900 after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic's Gamma...
Via
Benzinga
Mirati Therapeutics Posts Adagrasib Data In Lung Cancer Patients With CNS Metastases
June 06, 2022
Via
Benzinga
Expert Ratings for Mirati Therapeutics
May 24, 2022
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Mirati Therapeutics
May 05, 2022
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Via
Benzinga
The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed
June 07, 2022
Mirati Therapeutics said a combination using its KRAS drug appeared promising.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Open Lower; United Natural Foods Tops Q3 Views
June 07, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
June 07, 2022
Upgrades
Via
Benzinga
Mirati Therapeutics: Q1 Earnings Insights
May 04, 2022
Mirati Therapeutics (NASDAQ:MRTX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
Stocks Pacing for Weekly Losses Despite Strong Jobs Data
June 03, 2022
Wall Street is unpacking a strong jobs report this afternoon, though stocks are sliding as economists weigh the U.S. Federal Reserve's plans to continue hiking interest rates.
Via
Talk Markets
40 Stocks Moving In Friday's Mid-Day Session
June 03, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
70 Biggest Movers From Friday
May 31, 2022
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 27, 2022
Gainers
Via
Benzinga
Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash
May 27, 2022
Mirati is unlikely to carve out share with a drug that didn't differentiate, analysts say.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April
May 27, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 27, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
May 26, 2022
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
May 20, 2022
Upgrades
Via
Benzinga
Mirati Therapeutics's Return On Capital Employed Overview
May 20, 2022
According to data from Benzinga Pro, during Q1, Mirati Therapeutics's (NASDAQ:MRTX) reported sales totaled $709.00 thousand. Despite a 5.63% increase in earnings, the company posted a loss of $188.39...
Via
Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Preview For Mirati Therapeutics
May 03, 2022
Mirati Therapeutics (NASDAQ:MRTX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Mirati...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
April 13, 2022
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)
Via
Benzinga
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
March 09, 2022
Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst...
Via
Benzinga
Where Mirati Therapeutics Stands With Analysts
March 01, 2022
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.